Replies to post #39641 on DNAprint Genomics (DNAG)

[dr frudaky]

Gcbr It is not be as good as you think. The investors have essentially dismissed all the recent acqusitions as being of no consequence and the pps reflects that dismissal. The company is in dire need of significant revenues. Do you see any on the horizon? tia

[Virgil Hilts]

Thanks, Arch. I like this part the best. Sounds exactly like what we are doing with the Super EPO. This makes it pretty clear why DNAPrint and Kenna hooked up. Synergy, baby!


One challenge that could limit growth is the pharmaceutical industry's caution towards discovery tools that have not been thoroughly validated.

"In addressing this issue, companies need to work on generating success stories by developing an in-house compound and taking it till the commercial phase," Chitta said. "Companies can also work closely with discovery companies and a have a greater number of partnership deals where the risks and benefits can be shared."

Virgil